<DOC>
	<DOCNO>NCT02363439</DOCNO>
	<brief_summary>An extension study patient complete 24 week IMO-8400 study 8400-401 .</brief_summary>
	<brief_title>Extension Study IMO-8400 Patients With Waldenstr√∂m 's Macroglobulinemia Who Completed Study 8400-401</brief_title>
	<detailed_description>Patients evidence disease progression toxicity participate study 8400-401 continue receive IMO-8400 disease progression , adverse event investigator deem goal extend treatment IMO-8400 met .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Completed 24 week treatment Protocol 8400401 Grade 3 ( high ) adverse event assess treatmentrelated time course treatment Protocol 8400401 . Has evidence disease progression Protocol 8400401 . Has receive anticancer therapy IMO8400 since enrol Protocol 8400401 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>